Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
J Clin Hypertens (Greenwich). 2014 Feb;16(2):122-6. doi: 10.1111/jch.12243. Epub 2013 Dec 27.
The survival of patients with malignant hypertension (MHT) has considerably improved over the past decades. Data regarding the excess risk of mortality and the contribution of conventional cardiovascular risk factors are lacking. The authors retrospectively assessed cardiovascular risk factors and all-cause mortality in 120 patients with a history of MHT and compared them with 120 normotensive and 120 hypertensive age-, sex-, and ethnicity-matched controls. Total cholesterol, low-density lipoprotein cholesterol, and body mass index were lower in MHT patients compared with hypertensive controls, whereas blood pressure, high-density lipoprotein cholesterol, and smoking habit were similar. Median estimated glomerular filtration rate was lower in MHT patients compared with normotensive and hypertensive controls (both P<.01). The annual incidence of all-cause mortality per 100 patient-years was higher in MHT patients (2.6) compared with normotensive (0.2) and hypertensive (0.5) controls (both P<.01). Mortality of patients with a history of MHT remains high compared with normotensive and hypertensive controls. Patients with MHT had a more favorable cardiovascular risk profile compared with hypertensive controls but a higher prevalence of renal insufficiency.
恶性高血压(MHT)患者的存活率在过去几十年中得到了显著提高。然而,关于此类患者死亡风险增加的相关数据以及传统心血管危险因素的作用仍缺乏相关研究。作者回顾性评估了 120 例 MHT 病史患者的心血管危险因素和全因死亡率,并将其与 120 例血压正常和 120 例高血压患者进行了比较,这些患者在年龄、性别和种族方面均相匹配。与高血压对照组相比,MHT 患者的总胆固醇、低密度脂蛋白胆固醇和体重指数较低,而血压、高密度脂蛋白胆固醇和吸烟习惯则相似。与血压正常和高血压对照组相比,MHT 患者的估算肾小球滤过率中位数更低(均 P<.01)。MHT 患者的全因死亡率为每年每 100 患者年 2.6,高于血压正常患者(每年每 100 患者年 0.2)和高血压患者(每年每 100 患者年 0.5)(均 P<.01)。与血压正常和高血压对照组相比,MHT 患者的死亡率仍然较高。与高血压对照组相比,MHT 患者的心血管风险状况更有利,但肾功能不全的患病率更高。